Sri Lanka faces a growing epidemic in diabetes, with an estimated prevalence of one in five Sri Lankans living with diabetes.
Primary healthcare doctors are often the first point of contact for patients with diabetes, hence equipping them with specialized knowledge and skills is crucial for early diagnosis, effective management, and preventing complications.
The Memorandum of Understanding (MoU) signed between SLCE and Morison on 13th February 2024, reflects a shared commitment to bridge this gap in diabetes expertise and establish primary care as the first line of defence.
The course content developed and delivered by the SLCE, features an evidence-based curriculum, combining theoretical knowledge with practical applications, ensuring participants receive up-to-date knowledge that adheres to the latest Clinical Practice Guidelines and international standards.
The program aims to empower primary healthcare professionals to deliver comprehensive diabetes care in their daily practice, including therapeutics, lifestyle counselling, and complication prevention, ultimately leading to improved patient outcomes and reduced burden on the healthcare system.
The course, spanning four months, is now open for registrations for the first intake, and the collaboration aims to conduct two such programs per annum.
Dedicated to advancing endocrinology and diabetes care in Sri Lanka, the SLCE spearheads numerous initiatives to educate healthcare professionals on best practices in diabetes management.
Dr. Niranjala Meegoda Widanege, President of the Sri Lanka College of Endocrinologists stated,
"Equipping our primary healthcare doctors with specialized diabetes knowledge and skills is essential to tackle the growing epidemic effectively.
This training program marks a significant step forward in ensuring accessible and quality diabetes care for all Sri Lankans."
Dinesh Athapaththu, Managing Director, Morison Ltd commenting on the partnership added,
“We are pleased to collaborate with the SLCE to bring this meaningful initiative to life.
With a patient-centric approach across our value chain, we believe our latest efforts with the SLCE reflects our commitment to deliver a refreshing difference at a time it is most needed by the nation.”
Staying true to their purpose of “Making Premium Healthcare Affordable”, Morison strives to play a major role in the fight against diabetes by bringing the latest therapies closer to the nation with an offering that stands distinctively different with the best of quality and price.
Morison is a truly Sri Lankan pharmaceutical manufacturing company, with a rich legacy of over 60 years of industrial expertise.
Their new state-of-the-art manufacturing facility in Homagama, is the largest investment to date in the local pharma manufacturing industry.
Being the country’s largest pharma manufacturing facility for general tablets and liquids, it is also the first such facility in Sri Lanka to comply to European Union Good Manufacturing Practices (EU GMP) specifications.
As per their new strategic direction, Morison is committed to nurture an exclusive homegrown pharma brand built upon a value blend that is uniquely unapparelled, embarking on a journey upstream of elevating the Sri Lankan pharmaceutical industry to the heights it deserves.